Q32 Bio

The big question has been answered. In the 36-week trial of 33 patients with severe hair loss, bempikibart cut the severity score by 35.3 percent on average, and 40 percent of patients regained about 80 percent of their scalp hair. Roughly 700,000 Americans live with this condition and have very few good options, so a drug that actually works here matters.

Q32 Bio finished June with 106.3 million dollars in the bank, then raised another 200 million dollars in a July stock offering. That is enough money to carry the company all the way through its final-stage trial results, which is rare for a biotech this small. It also means they are not scrambling for cash at the worst possible moment.

Good trial results are not the same as a product on shelves. The bigger registration trial does not even start until the first half of 2027, and results come years after that. Q32 Bio lost 8.9 million dollars this quarter with zero revenue, and that burn continues the whole way through.

This is still a single-drug company. If the larger trial fails to repeat that 35.3 percent improvement, there is almost nothing else to fall back on, since a backup molecule is only in early lab testing. The 200 million dollar raise also created a lot of new shares, so every existing investor now owns a smaller slice of the company.